Literature DB >> 1203627

Effects of monoamine oxidase inhibition by clorgyline, deprenil or tranylcypromine on 5-hydroxytryptamine concentrations in rat brain and hyperactivity following subsequent tryptophan administration.

A R Green, M B Youdim.   

Abstract

1 The effect of various doses of tranylcypromine on the degree of inhibition of rat brain monoamine oxidase (MAO) using 5-hydroxytryptamine (5-HT), dopamine and phenylethylamine as substrates has been examined 120 min after injection of the inhibitor. The concentration of brain 5-HT was also examined both after tranylcypromine alone and also when L-tryptophan (100 mg/kg) had been given 30 min after the tranylcypromine. 2 All doses of tranylcypromine greater than 2.5 mg/kg totally inhibited MAO oxidation of 5-HT, phenylethylamine and dopamine as measured in vitro and produced a similar rise of brain 5-HT in vivo. When tryptophan was also given, there was a further rise of brain 5-HT, which was comparable after all doses of tranylcypromine above 2.5 mg/kg and the characteristic syndrome of hyperactivity made is appearance. 3 Clorgyline (a "Type A" MAO inhibitor), in doses up to 10 mg/kg, did not totally inhibit MAO activity towards phenylethylamine although it did inhibit 5-HT oxidation by 100%. Deprenil (a "Type B" MAO inhibitor) at doses up to 10 mg/kg did not fully inhibit 5-HT oxidation although phenylethylamine oxidation was inhibited almost completely. Administration of either compound alone did not produce as great an accumulation of brain 5-HT as that seen after tranylcypromine (2.5 mg/kg) and subsequent administration of tryptophan did not cause hyperactivity or the rise of brain 5-HT seen after tranylcypromine (2.5 mg/kg) plus tryptophan. 4 Administration of clorgyline plus deprenil (2.5 mg/kg of each) almost totally inhibited oxidation of both 5-HT and phenylethylamine; subsequent tryptophan administration resulted in a rise of brain 5-HT nearly as great as that seen following tranylcypromine (2.5 mg/kg) plus tryptophan and the animals became hyperactive. 5 No evidence was found pointing to the formation of any other 5-substituted indole in the brain following tranylcypromine plus L-tryptophan administration as suggested by others. 6 It is concluded that while 5-HT may normally be metabolized in the brain by "Tye A" MAO in vivo, when this form is inhibited, 5-HT can still be metabolized by "Type B" enzyme. It is only when both forms are almost totally inhibited that the largest rise of brain 5-HT is seen and subsequent tryptophan administration produces the hyperactivity syndrome.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1203627      PMCID: PMC1666694          DOI: 10.1111/j.1476-5381.1975.tb06946.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  23 in total

1.  Proceedings: Histochemical demonstration of an additional form of rat brain MAO.

Authors:  J E Gascoigne; D Williams; E D Williams
Journal:  Br J Pharmacol       Date:  1975-06       Impact factor: 8.739

2.  A SENSITIVE METHOD FOR SPECTROPHOTOFLUOROMETRIC ASSAY OF CATECHOLAMINES.

Authors:  C C CHANG
Journal:  Int J Neuropharmacol       Date:  1964-12

3.  Evidence that 5-methoxy-N, N-dimethyl tryptamine is a specific substrate for MAO-A in the rat: implications for the indoleamine dependent behavioural syndrome.

Authors:  R F Squires
Journal:  J Neurochem       Date:  1975-01       Impact factor: 5.372

Review 4.  Monoamine oxidases: the present status.

Authors:  M Sandler; M B Youdim
Journal:  Int Pharmacopsychiatry       Date:  1974

Review 5.  Multiple forms of mitochondrial monoamine oxidase.

Authors:  M B Youdim
Journal:  Br Med Bull       Date:  1973-05       Impact factor: 4.291

6.  Human brain monoamine oxidase: multiple forms and selective inhibitors.

Authors:  M B Youdim; G G Collins; M Sandler; A B Bevan Jones; C M Pare; W J Nicholson
Journal:  Nature       Date:  1972-03-31       Impact factor: 49.962

7.  The monoamine oxidases of brain: selective inhibition with drugs and the consequences for the metabolism of the biogenic amines.

Authors:  H Y Yang; N H Neff
Journal:  J Pharmacol Exp Ther       Date:  1974-06       Impact factor: 4.030

8.  The estimation of monoamine oxidase using 14C-labelled substrates.

Authors:  J Southgate; G G Collins
Journal:  Biochem Pharmacol       Date:  1969-09       Impact factor: 5.858

9.  Rapid method for the determination of 5-hydroxytryptamine and 5-hydroxyindoleacetic acid in small regions of rat brain.

Authors:  G Curzon; A R Green
Journal:  Br J Pharmacol       Date:  1970-07       Impact factor: 8.739

10.  Studies in vivo on the relationship between brain tryptophan, brain 5-HT synthesis and hyperactivity in rats treated with a monoamine oxidase inhibitor and L-tryptophan.

Authors:  D G Grahame-Smith
Journal:  J Neurochem       Date:  1971-06       Impact factor: 5.372

View more
  38 in total

Review 1.  Serotonin syndrome and drug combinations: focus on MAOI and RIMA.

Authors:  S E Hilton; H Maradit; H J Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1997       Impact factor: 5.270

2.  Increased L-DOPA-derived dopamine following selective MAO-A or -B inhibition in rat striatum depleted of dopaminergic and serotonergic innervation.

Authors:  O Sader-Mazbar; Y Loboda; M J Rabey; J P M Finberg
Journal:  Br J Pharmacol       Date:  2013-11       Impact factor: 8.739

3.  The effects of monoamine oxidase inhibitors on the ejaculatory response induced by 5-methoxy-N,N-dimethyltryptamine in the rat.

Authors:  L Rényi
Journal:  Br J Pharmacol       Date:  1986-08       Impact factor: 8.739

4.  Monoamine oxidase in rat reticulocytes: subcellular localization and identification of isoenzymes.

Authors:  K Quiring; S Hubertus
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977-11       Impact factor: 3.000

5.  Effect of nonselective and selective inhibitors of monoamine oxidases A and B on pethidine toxicity in mice.

Authors:  R Boden; R Botting; P Coulson; G Spanswick
Journal:  Br J Pharmacol       Date:  1984-05       Impact factor: 8.739

6.  Monoamine oxidase inhibitors increase preferentially extracellular 5-hydroxytryptamine in the midbrain raphe nuclei. A brain microdialysis study in the awake rat.

Authors:  P Celada; F Artigas
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-06       Impact factor: 3.000

7.  In vivo evidence for the reversible action of the monoamine oxidase inhibitor brofaromine on 5-hydroxytryptamine release in rat brain.

Authors:  N Bel; F Artigas
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-05       Impact factor: 3.000

8.  Effects of tranylcypromine stereoisomers, clorgyline and deprenyl on open field activity during long term lithium administration in rats.

Authors:  D F Smith
Journal:  Psychopharmacology (Berl)       Date:  1976-10-20       Impact factor: 4.530

9.  Differential behavioral syndrome evoked in the rats after multiple doses of SSRI fluoxetine with selective MAO inhibitors rasagiline or selegiline.

Authors:  Z Speiser; T Fine; L Litinetsky; S Eliash; E Blaugrund; S Cohen
Journal:  J Neural Transm (Vienna)       Date:  2007-09-07       Impact factor: 3.575

10.  Role of monoamine oxidase type A and B on the dopamine metabolism in discrete regions of the primate brain.

Authors:  M K Lakshmana; B S Rao; N K Dhingra; R Ravikumar; S Sudha; B L Meti; T R Raju
Journal:  Neurochem Res       Date:  1998-08       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.